Cargando…

Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurp...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzystanek, Marek, Pałasz, Artur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589301/
https://www.ncbi.nlm.nih.gov/pubmed/33096753
http://dx.doi.org/10.3390/ph13100326
_version_ 1783600547231694848
author Krzystanek, Marek
Pałasz, Artur
author_facet Krzystanek, Marek
Pałasz, Artur
author_sort Krzystanek, Marek
collection PubMed
description Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurposing of drugs used in other indications. In an open and naturalistic serious case study, 4 patients diagnosed with bipolar I disorder, chronically treated with a mood stabilizer, in whom at least two antidepressants were ineffective in the depressive phase, were treated with amantadine. The woman received 100 mg/day and 3 men received the target dose of 200 mg/day. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment. None of them experienced side effects or manic switch. To reduce the risk of a manic switch, the treatment with amantadine was discontinued 2 weeks after the improvement of depressive symptoms, and no recurrence of depressive symptoms was observed. Amantadine may be a further therapeutic option for the treatment of acute bipolar depression. The drug in this indication may act quickly and be well tolerated. Confirmation of the antidepressant efficacy of amantadine in this indication requires replication of the results and conducting clinical trials.
format Online
Article
Text
id pubmed-7589301
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75893012020-10-29 Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study Krzystanek, Marek Pałasz, Artur Pharmaceuticals (Basel) Communication Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurposing of drugs used in other indications. In an open and naturalistic serious case study, 4 patients diagnosed with bipolar I disorder, chronically treated with a mood stabilizer, in whom at least two antidepressants were ineffective in the depressive phase, were treated with amantadine. The woman received 100 mg/day and 3 men received the target dose of 200 mg/day. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment. None of them experienced side effects or manic switch. To reduce the risk of a manic switch, the treatment with amantadine was discontinued 2 weeks after the improvement of depressive symptoms, and no recurrence of depressive symptoms was observed. Amantadine may be a further therapeutic option for the treatment of acute bipolar depression. The drug in this indication may act quickly and be well tolerated. Confirmation of the antidepressant efficacy of amantadine in this indication requires replication of the results and conducting clinical trials. MDPI 2020-10-21 /pmc/articles/PMC7589301/ /pubmed/33096753 http://dx.doi.org/10.3390/ph13100326 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Krzystanek, Marek
Pałasz, Artur
Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
title Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
title_full Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
title_fullStr Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
title_full_unstemmed Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
title_short Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study
title_sort possibility of a new indication for amantadine in the treatment of bipolar depression—case series study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589301/
https://www.ncbi.nlm.nih.gov/pubmed/33096753
http://dx.doi.org/10.3390/ph13100326
work_keys_str_mv AT krzystanekmarek possibilityofanewindicationforamantadineinthetreatmentofbipolardepressioncaseseriesstudy
AT pałaszartur possibilityofanewindicationforamantadineinthetreatmentofbipolardepressioncaseseriesstudy